. Goss PE Ingle JN Pritchard KI . Extending aromatase-inhibitor adjuvant therapy to 10 years . N Engl J Med 2016 ; 375 : 209 – 219 . 4. Goss PE Ingle JN Martino S . Impact of premenopausal status at breast cancer diagnosis in women entered
Search Results
Costs and Benefits of Extended Endocrine Strategies for Premenopausal Breast Cancer
Janice S. Kwon, Gary Pansegrau, Melica Nourmoussavi, Geoffrey L. Hammond, and Mark S. Carey
Updates in the Treatment of Patients With Colorectal Cancer
Presented by: Smitha S. Krishnamurthi
just predicting a recurrence. It’s actually detecting residual disease. It appears to be the most useful prognostic assay, but there are unanswered questions, and we still don’t know if it can guide adjuvant therapy,” she said. Although ctDNA assays can
Disparities in the Use of Neoadjuvant Therapy for Resectable Pancreatic Ductal Adenocarcinoma
Jordan M. Cloyd, Chengli Shen, Heena Santry, John Bridges, Mary Dillhoff, Aslam Ejaz, Timothy M. Pawlik, and Allan Tsung
greater number of patients will be unable to complete the intended course of adjuvant therapy for similar reasons. 7 , 8 The administration of chemotherapy with or without radiation therapy (RT) before surgical resection is an alternative strategy that
Role of Adjuvant and Posttreatment Exercise Programs in Breast Health
Jennifer A. Ligibel
the completion of adjuvant therapy. Thus, physical activity has been shown to have several benefits for patients with breast cancer both during and after adjuvant therapy. No clear consensus exists on the “best” type of physical activity, but
The Challenges of Colorectal Cancer Survivorship
Crystal S. Denlinger and Andrea M. Barsevick
Edited by Kerrin G. Robinson
Fleming T Macdonald J . Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma . N Engl J Med 1990 ; 322 : 352 – 358 . 7 de Gramont A Boni C Navarro M . Oxaliplatin/5FU/LV in adjuvant colon cancer: updated efficacy
NCCN Guidelines Updates: Breast Cancer
Sharon H. Giordano, Anthony D. Elias, and William J. Gradishar
for advanced hormone-sensitive breast cancer at the NCCN 23rd Annual Conference. New Adjuvant Therapy Options for Patients With HER2-Positive Cancer Two new adjuvant treatment options for patients with HER2-positive disease are in the 2018 NCCN
NCCN Guidelines Updates: Breast Cancer
Melinda L. Telli, William J. Gradishar, and John H. Ward
personalize systemic adjuvant therapy choices,” Dr. Ward said. “The available assays have strong prognostic capability, and more data on this are coming.” Among the available assays are the 21-gene panel (Oncotype Dx), the 70-gene panel (MammaPrint), the 50
Uterine Neoplasms
Benjamin E. Greer, Wui-Jin Koh, Nadeem Abu-Rustum, Michael A. Bookman, Robert E. Bristow, Susana M. Campos, Kathleen R. Cho, Larry Copeland, Marta Ann Crispens, Patricia J. Eifel, Warner K. Huh, Wainwright Jaggernauth, Daniel S. Kapp, John J. Kavanagh, John R. Lurain III, Mark Morgan, Robert J. Morgan Jr, C. Bethan Powell, Steven W. Remmenga, R. Kevin Reynolds, Angeles Alvarez Secord, William Small Jr, and Nelson Teng
in endometrial carcinoma: overview of randomised trials . Clin Oncol (R Coll Radiol) 2008 ; 20 : 463 – 469 . 56 Fleming G . Adjuvant therapy for high-risk adenocarcinoma of the uterus . ASCO Educational Book 2008 : 230 – 233
Impact of Psychological Distress on Treatment Timeliness in Oncology Patients at a Safety-Net Hospital
Sheshadri Madhusudhana, Michelle Gates, Daulath Singh, Punita Grover, Mahathi Indaram, and An-Lin Cheng
adjuvant therapy has been shown to negatively impact outcomes in stage III colon cancer 5 and stage I–III breast cancer. 6 Although a few studies have found a paradoxical relationship of shorter treatment initiation intervals correlating with
Pancreatic Adenocarcinoma
Margaret A. Tempero, J. Pablo Arnoletti, Stephen Behrman, Edgar Ben-Josef, Al B. Benson III, Jordan D. Berlin, John L. Cameron, Ephraim S. Casper, Steven J. Cohen, Michelle Duff, Joshua D.I. Ellenhorn, William G. Hawkins, John P. Hoffman, Boris W. Kuvshinoff II, Mokenge P. Malafa, Peter Muscarella II, Eric K. Nakakura, Aaron R. Sasson, Sarah P. Thayer, Douglas S. Tyler, Robert S. Warren, Samuel Whiting, Christopher Willett, and Robert A. Wolff
pancreatic cancer, then surgical consultation is recommended. Restaging with high-quality abdominal and chest imaging is also recommended after surgery for resectable disease and before initiation of adjuvant therapy (see page 980). It should also be